Phreesia, a company engaged in patient intake, outreach, and activation, has announced the acquisition of MediFind, a health technology company, that utilizes advanced analytics to aid patients, particularly those with severe, chronic, and rare diseases, in obtaining superior care swiftly.

MediFind employs machine learning and proprietary algorithms to routinely assess medical information across extensive datasets. This process determines the leading doctors in specific conditions and fields based on criteria such as their research output, patient volume, and peer reputation. MediFind classifies these doctors into four levels of expertise: elite, distinguished, advanced, and experienced, with elite-level doctors being global leaders in their respective fields.

MediFind’s CEO Patrick Howie, who is now Vice President of Product Management at Phreesia, founded the company following his brother’s diagnosis with a rare cancer. Howie shared his pride in MediFind’s ability to identify leading doctors in their fields, expressing his enthusiasm for the opportunity to reach a larger audience through Phreesia’s extensive network.

Phreesia’s Senior Vice President, David Linetsky, highlighted the alignment between Phreesia’s mission and MediFind’s focus. He stated, “At Phreesia, we’re always thinking about how to arm patients with the right tools and relevant information,” He welcomed MediFind colleagues to join in addressing these challenges collaboratively.

  David Linetsky, MediFind, Patrick Howie, Phreesia, USA